Efficacy of BCG Therapy is a Function of Bladder Tumor Immun Microenvironment

Technology #2011-245

Immune responses directed toward many cancers are characterized by targeted cell-killing activities mediated by cytotoxic T cells (a.k.a. Thl responses). However, certain tumors such as bladder cancer, instead appear to elicit immune responses that are traditionally linked with allergies (a.k.a. Th2 responses). These immune responses also include the tissue recruitment of rare white blood cells known as eosinophils. Patients having an initial bladder tissue biopsy with more Th2 lymphoid cells than Th1 lymphoid cells or more eosinophil infiltration, can be identified or classified as being likely to respond to BCG therapy.